King Pharmaceuticals KG Increase in accrued expenses and other liabilities
Increase in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's increase in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's increase in accrued expenses and other liabilities?
- King Pharmaceuticals (KG) reported increase in accrued expenses and other liabilities of $5.56M in Q1 2026.
- How has King Pharmaceuticals's increase in accrued expenses and other liabilities changed year-over-year?
- King Pharmaceuticals's increase in accrued expenses and other liabilities increased by 2369.0% year-over-year, from -$245K to $5.56M.